



Psynova Neurotech Wins Prestigious Medical Futures Award

June 2007: Psynova Neurotech is pleased to announce it is this year's winner of The Overall Mental Health & Neurosciences Innovation Award in the Medical Futures Innovation Awards.

Consultant Psychiatrist, Sabine Bahn has been judged the overall winner for the Mental Health and Neurosciences category. Her entry Psynova Neurotech - is a blood test to diagnose mental health diseases such as depression or schizophrenia. Using novel bio-markers the team are developing a simple blood test to pick up those predisposed to mental illness long before they ever present with symptoms. Mental illness now affects one in three people and the World Health Organisation predicts that depression will be the second biggest healthcare burden on mankind by 2020, ahead of cancer and HIV, demonstrating the strong need for this technology.

Medical Futures is an organisation that promotes and supports innovation within the healthcare industry. The Awards, widely regarded in the industry as the healthcare Oscars, attract huge interest from the medical and business world. This year was no exception; with a record number of entries from pioneering frontline medical practitioners competing to be the next breakthrough in healthcare innovation for what has become the UK's most sought after healthcare accolade.

Andy Goldberg, founder of Medical Futures comments: "Healthcare touches every person at some stage in their lives. It is sad that almost all of the successful medical innovations, such as Penicillin, the hip replacement and the catheter, took 20 years or more to go from the inventor's mind to the point where they actually benefited a patient. These Awards aim to catalyse brilliant ideas from the very people who deliver care and make them available to patients. After all, one doctor's idea has the potential to change millions of lives around the world."

Sabine Bahn, co-founder of Psynova Neurotech comments: "We are so pleased to have won. Current diagnostic methods have remained unchanged for the last 100 years. It is vital that methods of diagnosis in this field are brought up to date, ensuring we stem the rise in people suffering from these diseases."

The winners were officially announced at the prestigious awards ceremony on the 14th June in central London hosted by Joanna Lumley OBE and Rory Bremner. Over 750 guests attended the charitable dinner, in aid of SANE, an organisation that helps provide information and support for people and their families with mental illness.

Press Release

For further information on Psynova Neurotech Ltd.
and all other media enquiries, please contact:

Paul Rodgers, Director, Psynova Neurotech Ltd

Telephone/Fax: +44 (0) 1223 703146

Mobile: +44 (0) 7802 157393

paul.rodgers@psynova.com

www.psynova.com



NOTES TO EDITORS:

Psynova Neurotech Ltd. is a new company, established in 2005 by Dr Sabine Bahn MD, Ph.D, MRCPsych, and Prof Chris Lowe PhD of the University of Cambridge, for the commercial development and exploitation of novel biomarkers for Neuropsychiatric illnesses.

Building on 12 years of ground-breaking research by Dr Bahn, Psynova Neurotech has close links with Bahn's laboratory within the newly established Centre for Neuropsychiatric Research (CCNR) at the University of Cambridge. Initially concentrating on Schizophrenia and Bipolar Affective Disorder (previously referred to as manic depression) Psynova Neurotech intends to longer term, move into related therapeutic areas, such as depression, neurodegenerative disorders and substance abuse, as well as sleep and eating disorders, where it has extensive relevant expertise.

At present there are no validated biomarkers and diagnostics for these disorders, nor are the underlying disease processes understood, meaning symptomatic relief only, from current medications on offer. Psynova Neurotech intends to address all of these deficiencies.

ENDS